



Published in final edited form as:

Leukemia. 2022 November ; 36(11): 2621–2633. doi:10.1038/s41375-022-01719-6.

Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition

Shaowei Qiu^{1,2}, Harish Kumar¹, Chengcheng Yan¹, Hui Li¹, Andrew J. Paterson¹, Nicholas R. Anderson¹, Jianbo He¹, Jing Yang³, Min Xie³, David K. Crossman⁴, Rui Lu¹, Robert S. Welner¹, Ravi Bhatia¹

¹Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL

²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China

³Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL

⁴Genomics Core Facility, University of Alabama at Birmingham, Birmingham, AL

Abstract

The FLT3-ITD mutation is associated with poor prognosis in acute myeloid leukemia (AML). FLT3 tyrosine kinase inhibitors (TKIs) demonstrate clinical efficacy but fail to target leukemia stem cells (LSC) and do not generate sustained responses. Autophagy is an important cellular stress response contributing to hematopoietic stem cells (HSC) maintenance and promoting leukemia development. Here we investigated the role of autophagy in regulating FLT3-ITD AML stem cell function and response to TKI treatment. We show that autophagy inhibition reduced quiescence and depleted repopulating potential of FLT3-ITD AML LSC, associated with mitochondrial accumulation and increased oxidative phosphorylation. However, TKI treatment reduced mitochondrial respiration and unexpectedly antagonized the effects of autophagy inhibition on LSC attrition. We further show that TKI-mediated targeting of AML LSC and committed progenitors was p53-dependent, and that autophagy inhibition enhanced p53 activity and increased TKI mediated targeting of AML progenitors, but decreased p53 activity in LSC and reduced TKI-mediated LSC inhibition. These results provide new insights into the role of autophagy in differentially regulating AML stem and progenitor cells, reveal unexpected antagonistic effects of combined oncogenic tyrosine kinase inhibition and autophagy inhibition in

Corresponding author: Ravi Bhatia, MD, Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, 1802 6th Avenue South, North Pavilion, Room 2555C, Birmingham, AL – 35294, Ph: (205) 934-9591, Fax: (205) 996-5975, rbbhatia@uabmc.edu.

Author contributions


Conceptualization: S.Q., R.B.; Methodology: S.Q., H.K., C.Y., A.P., N.A., and R.B.; Investigation: S.Q., H.K., N.A., H.L., J.H., J.Y., M.X., D.C., R.L., R.W., and R.B.; Formal analysis: S.Q., R.B.; Writing – Original Draft: S.Q., R.B.; Writing–Review & Editing: R.B., S.Q., A.P.; Funding Acquisition: R.B.; Supervision: R.B.

Competing Interests

The authors have declared that no competing interests exist.

AML LSC, and suggest an alternative approach to target AML LSC quiescence and regenerative potential.

Graphical Abstract



Introduction

Acute myeloid leukemia (AML) leukemic stem cells (LSC) reside at the apex of a cellular hierarchy that initiates and maintains disease.¹ LSC demonstrate properties of self-renewal, quiescence, and chemoresistance. LSC persistence after therapy and contribute to resistance and relapse. An internal tandem duplication (ITD) in the juxta-membrane domain of the FMS-like tyrosine kinase-3 (FLT3) is a common molecular abnormality in AML.^{2,3} FLT3-ITD mutations predict for increased risk of relapse and poor survival. FLT3 tyrosine kinase inhibitors (TKIs) have shown benefit in the treatment of FLT3-ITD AML. However, responses are not sustained and resistance remains a challenge.⁴⁻⁷ There is considerable interest in understanding mechanisms of persistence of FLT3-ITD AML LSC after treatment.

Autophagy is a cellular stress response that maintains homeostasis by lysosomal degradation and recycling of damaged organelles and protein aggregates.⁸ Autophagy plays a crucial role in aging, cancer and metabolic disease.^{9,10} Autophagic flux is enhanced in hematopoietic stem cells (HSC), and important for maintaining HSC function.¹¹⁻¹³ Lentiviral knockdown of autophagy genes Atg5 and Atg7 leads to impaired HSC engraftment. Atg7^{null} or Atg5^{null} mice develop anemia, loss of HSC function and myeloproliferation. Autophagy-deficient HSC show mitochondrial accumulation, metabolic activation, increased proliferation, myeloid differentiation, and impaired self-renewal.^{12,14} The tumor suppressor, p53, is also an important component of stress signaling, and has an important relationship between autophagy. Autophagy suppresses p53, and suppression of p53 by autophagy may contribute to tissue preservation and tumor promotion.¹⁵

Autophagy participates in leukemia development, maintenance, and treatment resistance.¹⁶ Autophagy inhibition has been explored as a treatment strategy in AML¹⁷⁻²² and CML.²³⁻²⁵

AML CD34+ cells were more sensitive to the autophagy inhibitor hydroxychloroquine (HCQ) than normal CD34+ cells.¹⁸ Deletion of Atg5 or Atg7 in MLL-ENL leukemic mice prolonged survival, reduced LSC and enhanced chemosensitivity.²⁶ Autophagy was required for MLL-AF9 AML initiation.²⁷ However, the role of autophagy in modifying FLT3-ITD LSC function and treatment response is not clear.

Lys05 is a highly potent, second generation autophagy inhibitor.²⁸ Like HCQ, Lys05 accumulates in and deacidifies lysosomes, impairing autophagy flux.^{23, 28} Here we studied the effect of Lys05 in FLT3-ITD AML, using patient samples and a genetic mouse model. We show that autophagy inhibition enhances mitochondrial respiration and activates and depletes FLT3-ITD AML LSC. However, TKI treatment unexpectedly antagonizes the effects of autophagy inhibition on LSC attrition by inhibiting mitochondrial respiration. We further show that TKI-mediated targeting of AML LSC and progenitors is p53-dependent. Autophagy inhibition enhances p53 activity and increases TKI-mediated inhibition of AML progenitors. In contrast, autophagy inhibition reduces p53 activity in LSC and reverses TKI-mediated inhibition of LSC. These findings provide new insights into the role of autophagy in modulating leukemic stem and progenitor cell function and response to tyrosine kinase inhibition.

Materials and Methods

Mice:

C57BL/6 mice were from Jackson Laboratory (Bar Harbor, ME), and C57BL/6.SJL mice from Charles River Laboratories (Frederick, MD). Mx1-Cre Tet2^{fl/fl} mice and FLT3-ITD^{ki} mice (Jackson Laboratory) were crossed to generate FLT3-ITD^{ki}/Mx1-Tet2^{f/f} mice. Cre activity was induced by intraperitoneal (IP) injections of polyinosine-polycytosine (poly(I:C)) (12.5mg/Kg) every other day for 7 doses. C57BL/6-Tg(CAG-RFP/EGFP/Map11c3b) autophagy reporter mice were developed by Min Xie, and utilize differential pH sensitivities for red fluorescent protein (RFP; pKa 4.5) and enhanced green fluorescent protein (EGFP; pKa 5.9).²⁹ NOD.Cg-Prkdc^{scid} IL2rg^{tm1Wjl}/SzJ mice (NSG) and NOD.Cg-Rag1^{tm1Mom} Il2rg^{tm1Wjl} Tg(CMV-IL3, CSF2, KITLG) (NRGS) mice were purchased from Jackson Laboratory. All experiments were performed using 8-10 weeks old mice of both sexes. Sample size was based on previous studies that established the number of mice per group required to detect significant differences. Mice were randomized between treatment groups based on sex and on levels of engraftment. Blinding was not used. Mouse care was in accordance with federal guidelines and protocols approved by the UAB Institutional Animal Care and Use Committee (IACUC).

Human samples:

Peripheral blood (PB) and bone marrow (BM) samples were obtained from FLT3-ITD AML and non FLT3-ITD AML patients seen at the University of Alabama at Birmingham (UAB). Patients characteristics are shown in Table S1. Normal peripheral blood stem cells (PBSCs) were obtained from transplant donors. Mononuclear cells were isolated by Ficoll-Hypaque (Sigma Diagnostics, St. Louis, MO) centrifugation. CD34+ cells were isolated using immunomagnetic beads (Miltenyi Biotech, Auburn, CA). CD34+CD38-

and CD34⁺CD38⁺ cells were selected by flow cytometry. MV4;11 cells were obtained from ATCC and MOLM-13 cells from the German Collection of Microorganisms and Cell Cultures. Human sample acquisition was approved by the UAB Institutional Review Board in accordance with assurances filed with the Department of Health and Human Services and met all requirements of the Declaration of Helsinki. Informed consent was obtained from AML patients and transplant donors.

Stem/progenitor cell culture:

Human CD34⁺ cells were cultured in Stemspan serum-free enhanced medium (SFEM; StemCell Technologies) with human interleukin-3 (IL-3)(20ng/ml), FLT3 ligand (FLT3L) (100ng/ml); thrombopoietin (TPO)(50ng/ml); stem cell factor (SCF) (100ng/ml)(PeproTech, Cranbury, NJ) for 48 hours.³⁰ Mouse C-kit⁺ cells were cultured in StemSpan™ SFEM medium supplemented with murine IL-3 (10ng/ml); GM-CSF (10ng/ml); SCF (25ng/ml) and TPO (25ng/ml)(PeproTech) for 24 hours.¹¹

Mouse hematopoietic cell analyses.

BM cells from leukemic FLT3-ITD^{ki} Mx1-cre Tet2^{fl/fl} mice (CD45.2) were transplanted into irradiated (400cGy x 2) CD45.1 mice. Following leukemia development, mice were treated with Lys05 (20mg/kg/day, IP), AC220 (10mg/kg/day, oral gavage) or vehicle for 2 weeks. Secondary repopulation was analyzed by transplanting pooled BM from treated mice (2×10⁶ cells/mouse) with equal numbers of wild-type (WT) cells (CD45.1) into CD45.1 mice irradiated at 800cGy. Blood, BM, and spleen cells were labeled with anti-CD45.1, CD45.2 and lineage-specific antibodies. Long-term HSC (LT-HSC; Lin- Sca1+cKit+Flt3-CD150+CD48⁻), short-term HSC (ST-HSC; Lin- Sca1+cKit+ Flt3-CD150-CD48⁻), multipotent progenitors (MPP; Lin- Sca1+cKit+Flt3-CD48⁺) and granulocyte-macrophage progenitors (GMP; Lin-Sca1-c-Kit+CD34+FcR2II/III^{hi}) were analyzed using a BD LSR Fortessa X-20 flow cytometer (BD, San Jose, CA) and FlowJo (Version 8.5.2).³¹

For xenograft experiments, 5×10⁶ peripheral blood mononuclear cells from FLT3-ITD AML patients were incubated for 30 minutes with OKT3 antibody (Bio X Cell, BE0001-2) and transplanted into irradiated NSG or NRGs mice. BM and spleen cells were analyzed for human CD45⁺ cells and subpopulations by labeling with human antibodies (CD34, CD33, CD38, CD14,CD11b, CD3, CD19). Details of antibodies are shown in Table S2.

For cell cycle analysis, BM cells were labeled for surface markers, treated with Cytofix/Cytoperm™ (BD), labeled with Ki67 and DAPI, and analyzed by flow cytometry.

RNA interference.

AML CD34⁺ cells were transfected with siRNAs to ATG5 (SMARTpool,Cat:M-004374-04-0005, Dharmacon-Horizon Discovery, Lafayette, CO) using an Amaxa cell Nucleofector IIb (Lonza, Basel, Switzerland).³² FITC-labeled siRNA (Silencer™ Select Negative Control No. 1 siRNA, Thermo Fisher, Waltham, MA) was used to evaluate transfection efficiency, with positivity above 90%. MV4-11 and Molm13 (MOI=2) were transduced with PLKO lentivirus vectors expressing ATG5 or control shRNA with polybrene (4µg/ml). Transduction efficiency exceed

90%. LSK cells were transduced with SI506A-1 vectors (System Bioscience, SBI) expressing EF1a-GFP-T2A-Puro and ATG5 (5'-TATGAAGAAAGTTATCTGGGTA-3'), p53 (5'-GTACATGTGTAATAGCTCC-3') or control shRNA. LSK cells from FLT3-ITD leukemic mice were cultured overnight in SFEM medium with cytokines (10ng/ml SCF; 10ng/ml TPO) and exposed to lentivirus (MOI=100) and TransDux (SBI) with centrifugation at 2500rpm for 90 minutes. Transduction efficiency after 48 hours of culture for control, ATG5 and P53 shRNA expressing vectors was 82.7%, 79.8% and 78.3% respectively. Transduced cells were injected into irradiated recipient CD45.1 mice (25,000 CD45.2 LSK cells plus 200,000 CD45.1 supportive cells per mouse).

Extracellular flux analysis (Mito Stress Test).

c-kit⁺ cells were isolated using immunomagnetic beads (Miltenyi Biotech). Oxygen consumption rate (OCR) was measured using the Seahorse XF96 analyzer (Agilent) as previously described.³¹

Statistics.

Results are shown as mean plus/minus standard error of the mean (SEM). Significance values were calculated using Prism version 9.0 software (GraphPad Prism, La Jolla, CA) using parametric and nonparametric t tests (Mann-Whitney test), or analysis of variance as appropriate based on normality of distribution. Survival was analyzed using Kaplan-Meier analysis.

Results

Autophagy inhibition reduces human FLT3-ITD AML CD34⁺ cell growth and enhances TKI sensitivity in vitro

MV4-11 and Molm13 FLT3-ITD AML cells were transduced with a GFP-LC3-RFP-LC3 GFP autophagy reporter plasmid (Fig 1A). The expressed protein is cleaved by ATG4 proteases into equimolar amounts of GFP-LC3 and RFP-LC3. GFP-LC3 is recruited to the autophagosome and degraded, whereas RFP-LC3 remains cytosolic and intact. The GFP:RFP signal ratio inversely correlates with autophagic activity.³³ Reporter function was validated by showing that autophagy inducers (Torin, Rapamycin, and PP242) reduced GFP:RFP ratios, and autophagy inhibitors (Lys05, CQ, and SAR405) increased GFP:RFP ratios (Fig S1A). To study the relationship of autophagy to TKI and Lys05 sensitivity, cells with low autophagy flux (AT-low, top 20% of GFP-expressing cells) or high autophagy flux (AT-high, bottom 20% of GFP-expressing cells) were purified (Fig 1A). Differences in GFP:RFP ratios between AT-high and AT-low cells were maintained after 72 hours culture (Fig 1A, Fig S1B). AT-high cells showed reduced apoptosis after treatment with the Flt3 TKI AC220, and increased apoptosis after exposure to the autophagy inhibitor Lys05, compared to AT-low cells (Fig 1A, Fig S1C). Autophagy inhibition via shRNA-mediated knockdown of ATG5 enhanced sensitivity of FLT3-ITD+ Molm13 and MV4-11 but not non-FLT3-ITD OCI-AML3 AML cells to the AC220 (Fig 1B, Fig S1D). Similarly treatment with the autophagy inhibitors Lys05 or SAR405 treatment enhanced sensitivity of Molm13 and MV4-11 but not OCI-AML3 AML cells to the FLT3 TKIs AC220 or Giltertinib (Fig

1C, Fig S1E). The combination of AC220 and Lys05 led to synergistic growth inhibition (Combination index 0.59 to 0.88) (Fig S1F).

CD34+ progenitor cells and CD34- mature cells from FLT3-ITD AML patients showed similar levels of autophagy flux. Normal and FLT3-ITD AML CD34+ progenitors also showed similar autophagy flux (Fig S2A). Lys05 inhibited autophagy flux in AML CD34+ cells, evidenced by increased LC3B expression, LC3B-II expression, and LC3B punctae formation (Fig 2A, Fig S2B). AC220 treatment did not affect autophagy flux in AML CD34+ cells, in contrast to prior reports for FLT3-ITD AML cell lines or unselected primary cells.³⁴ Lys05 reduced FLT3-ITD AML CD34+ and CD34- cell growth and survival, and the combination of Lys05 and AC220 synergistically increased inhibition of cell growth and survival compared to AC220 alone (Fig 2B, Fig S2C-D). In contrast, Lys05 did not affect survival and minimally affected growth of non-FLT3-ITD AML CD34+ and CD34- cells (Fig 2B, Fig S2C). ATG5 knockdown using siRNA also significantly reduced AML CD34+ cell growth and cell survival, and ATG5 knockdown cells showed increased inhibition with AC220 compared to control siRNA treated cells (Fig 2C). Autophagy inhibition with Lys05 only modestly inhibited normal CD34+ cell proliferation and did not affect survival (Fig S2E). We conclude that autophagy inhibition selectively targets FLT3-ITD AML compared with non-FLT3-ITD AML and normal CD34+ progenitor cells and enhances their sensitivity to TKI.

Autophagy inhibition enhances TKI-mediated targeting of primary human FLT3-ITD cells engrafted in immunodeficient mice

We evaluated effects of autophagy inhibition *in vivo* on primary FLT3-ITD AML cells xenografts established in immunodeficient NSG or NRGS mice (Fig 3A). Mice were injected with primary human cells from three FLT3-ITD AML patients. Following establishment of engraftment 8-12 weeks after transplantation, mice were treated with vehicle, AC220 (10mg/kg/day, gavage), Lys05 (20mg/kg/day, IP) or the combination for 3 weeks. We confirmed that *in vivo* treatment with Lys05 increased LC3b accumulation in engrafted human CD45+ cells (Fig S3A). Lys05 treatment did not consistently impact AML CD45+ cells engraftment. AC220 reduced human CD45+ cells in 2 of the 3 samples (#173 and #395). Combined treatment with Lys05 and AC220 led to significantly increased inhibition of human CD45+ cells compared to AC220 alone in all samples (Fig 3B, Fig S3B). These results indicate that autophagy inhibition enhanced TKI-mediated targeting of primary human FLT3-ITD cells *in vivo* even when cells were insensitive to AC220 alone.

Quiescence is a key characteristic of LSC. Lys05 treatment reduced primitive CD34+CD38- cells in G₀ and increased cells in G₁. Surprisingly, addition of AC220 to Lys05 increased CD34+CD38- cells in G₀ compared to Lys05 alone, indicating that AC220 inhibited Lys05-induced cell cycling (Fig 3C). Lys05 did not significantly affect cell cycle in CD34+CD38+ progenitor cells (Fig S3C). These observations indicate that autophagy inhibition reduces quiescence of primitive FLT3-ITD AML cells, but that FLT3 kinase inhibition counters this effect.

Autophagy inhibition enhances TKI-mediated inhibition of FLT3 ITD AML progenitors and increases AML stem cell cycling in a genetic mouse model

We investigated the effect of autophagy inhibition on FLT3-ITD AML LSC using a genetic mouse model generated by crossing FLT3-ITD^{ki} and Mx1-Cre Tet2^{fl/fl} mice. This model is similar to a previously reported FLT3-ITD AML model generated by crossing FLT3-ITD^{ki} and Vav-Cre Tet2^{fl/fl} mice.³⁵ Mice develop a lethal AML-like disease (median survival 200 days), and LSC are present within primitive Lin⁻ Sca-1⁺ Kit⁺ (LSK) cells, which include ST-HSC and MPP, but are depleted of LT-HSC. LSK cells in this model are reported to show limited sensitivity to TKI treatment.³⁵ We found that primitive LSK cells from AML mice showed modestly enhanced autophagy flux compared to differentiated cells (Fig S4A), but LSK cells from AML and normal mice showed similar autophagy flux (Fig S4B).

AML BM cells (CD45.2) were transplanted into irradiated recipients (CD45.1) to generate cohorts with similar leukemia onset. Mice were treated with Lys05, AC220, or the combination for 2 weeks (Fig 4A). We confirmed that Lys05 inhibited autophagy flux in vivo by showing that Lys05 treatment enhanced maintenance of EGFP puncta in BM cells of CAG-RFP/EGFP/Map11c3b reporter mice (Fig S4C).³⁶ Circulating WBC and neutrophils (Fig S4D) were reduced in all treatment arms in AML mice at time of completion of treatment. AC220 and combination treatment effectively reduced spleen size, splenic GMP, MPP and STHSC (Fig S4E), compared to vehicle, consistent with reduction in disease burden. AC220 and combination treatment reduced BM GMP but not BM MPP and ST-HSC (Fig 4B, Fig S4F). In wild-type mice, Lys05 did not affect WBC, increased neutrophils slightly and reduced BM GMP without affecting MPP, ST-HSC and LT-HSC (Fig S4G) after 2 weeks of treatment.

Lys05 treatment significantly reduced the proportion of BM LSK cells in G₀ and increased cells in G₁ compared to vehicle, indicating enhanced cell cycling. On the other hand, AC220 or the combination of Lys05 and AC220 did not significantly alter LSK cell cycling (Fig 4C). Similar results were seen for ST-HSC (not shown). Lys05 and AC220 treatment did not affect cell cycle in GMP cells, but the combination of Lys05 and AC220 modestly increased GMP cycling (Fig S4H). Treatment of wild type mice with Lys05 led to modest reduction in BM LSK cells in G₀, but to a lesser extent than AML LSK cells (Fig S4I).

Autophagy inhibition reduces repopulating capacity of FLT3-ITD AML stem cells in a genetic mouse model

The effect of treatment on LSC repopulation capacity was evaluated by transplanting BM cells from treated mice (CD45.2) into wild-type secondary recipient mice (CD45.1) with competitor BM cells (CD45.1) (Fig 5A). Lys05-treated cells generated reduced total donor chimerism, donor myeloid chimerism, BM cellularity, donor myeloid cells, B cells, T cells, GMP, MPP and ST-HSC in BM of secondary recipients compared to vehicle treated cells. AC220-treated cells also generated reduced repopulation in secondary recipients. Surprisingly, cells from mice receiving combination treatment did not show reduced secondary repopulation compared to cells from vehicle treated mice, indicating that combination of AC220 with Lys05 has antagonistic effects on AML LSC repopulating capacity (Fig 5B, Fig S5A-S5D).

We evaluated the effects of genetic targeting of autophagy in murine AML stem cells by transducing FLT3-ITD AML cells with lentivirus vectors expressing ATG5-shRNA or control-shRNA and GFP. We confirmed reduction in ATG5 mRNA and protein levels (Fig 5C, Fig S5E) in LSK cells. Mice engrafted with ATG5 or control shRNA expressing LSK cells were treated with AC220 or vehicle for 2 weeks. ATG5 knockdown resulted in increased numbers of BM GFP⁺ cells, myeloid cells, GMP and ST-HSC. AC220 treatment reduced ATG5-knockdown GFP⁺ populations but not control GFP⁺ populations (Fig 5C, Fig S5F). These results are consistent with increased cell cycling following autophagy inhibition. Differences between results of ATG5 shRNA and Lys05 treatment likely reflect differential effects of chronic, long-standing autophagy inhibition with ATG5 shRNA versus acute inhibition with Lys05 and targeting and upstream autophagy gene versus the lysosome.

These results indicate that autophagy inhibition enhances AML LSC cycling and reduces their repopulating potential. However, increased AML LSC attrition is antagonized by TKI treatment, indicating that it is FLT3 kinase dependent. In contrast, the combination of Lys05 and TKI synergistically inhibits AML progenitor cells.

Mitochondrial respiration is enhanced in AML stem cells following autophagy inhibition but is reduced in combination with tyrosine kinase inhibition

We performed RNA sequencing on AML LSC (LSK) and progenitor cells (GMP) from mice treated with Lys05, A220 and the combination of Lys05 and AC220. Gene set enrichment analysis (GSEA) confirmed enrichment of quiescence (Fig S6A), AML stemness,³⁷ and HSC signatures in AML LSK cells (Fig S6B), and GMP and myeloid signatures³⁸ in AML GMP cells (Fig S6C). Lys05-treated AML LSK cells showed enhanced cell cycle and reduced quiescence signatures compared to vehicle treated cells (Fig 6A-6B). Quiescence signatures were unchanged in LSK cells treated with AC220 or the combination of AC220 and Lys05 (Fig S6D). These results were consistent with our cell cycle analysis (Fig 4C).

Lys05-treated LSK cells were enriched for mitochondrial, oxidative phosphorylation (OXPHOS) (Fig 6C, Fig S6E), long chain fatty acid synthesis, fatty acid beta oxidation, TCA cycle and glutathione metabolism gene signatures (Fig S6F). However, OXPHOS signatures were downregulated in LSK cells treated with AC220 compared to vehicle. OXPHOS signatures were also reduced in LSK cells treated with a combination of AC220 and Lys05 compared to vehicle or to Lys05 alone (Fig 6C).

Lys05 treatment increased mtDNA copy number in LSK cells, indicating increased mitochondrial mass (Fig 7A), but decreased mitochondrial membrane potential measured by TMRE labeling (Fig 7B), suggesting that autophagy inhibition allows accumulation of stressed mitochondria. We evaluated mitochondrial respiration by extracellular flux analysis using the Seahorse apparatus to measure oxygen consumption rate (OCR). In view of the high cell number requirement, BM c-Kit⁺ progenitor cells rather than purified LTHSC were used for these assays. Lys05 modestly increased maximal mitochondrial respiratory capacity, but not basal or ATP-linked respiration. AC220 did not significantly affect OCR by itself, but markedly reduced basal and maximal OCR with Lys05 (Fig 7C). Since increased mitochondrial respiration plays a critical role in promoting HSC activation and

differentiation, reduced mitochondrial respiration may explain the antagonistic effects of TKI on Lys05-mediated LSC attrition.

Autophagy inhibition differentially modulates p53 activity in TKI-treated FLT3-ITD AML progenitor and stem cells

We evaluated the relationship between autophagy and p53 activation in FLT3-ITD AML cells. Autophagy induction (Torin, starvation) reduced p53 protein levels (Fig S7A) whereas autophagy inhibitors (CQ, SAR405) increased p53 protein levels (Fig S7B). Autophagy inhibition (Lys05) prolonged p53 protein half-life in Cycloheximide-treated cells whereas autophagy induction (Torin) enhanced p53 degradation (Fig S7C). Moreover p53 protein levels were increased in AT-low cells compared to AT-high cells (Fig S7D). These observations together indicate that p53 may be a substrate of the autophagosome. We further show that p53 knockdown abrogated effects of Lys05 on survival and growth of FLT3-ITD AML cells (Fig S7E), and of AC220 and combined Lys05 and AC220 treatment on survival (Fig S7F-S7G).

RNA sequencing showed that p53 gene signatures were enriched in GMP from Lys05 and AC220 treated mice compared with AC220 treated mice (Fig 8A). RT-Q-PCR analysis confirmed that p53 target genes p21, Noxa and Puma were upregulated in GMP from combination compared to AC220 treated mice (Fig 8A). p53 target genes p21, Bax, Noxa and Puma were also upregulated in human FLT3-ITD AML CD34+ progenitor cells treated with the combination compared to AC220 alone (Fig 8A). In contrast, p53 gene signatures and p53 target genes were reduced in LSK from Lys05 and AC220 treated mice compared with AC220 treated mice (Fig 8B). Therefore autophagy inhibition enhances p53 activity in TKI-treated progenitor cells, but paradoxically reduces p53 activity in TKI-treated LSC.

We evaluated the role of p53 in murine FLT3-ITD LSC using lentivirus vectors expressing p53-shRNA (Fig S7H). We confirmed effective inhibition of p53 mRNA and protein expression in LSK cells (Fig 8C, Fig S7I). Mice engrafted with control-shRNA and p53-shRNA expressing LSK cells were treated with vehicle or Lys05 or AC220 for 2 weeks. p53 shRNA expressing GFP+ cells and GFP+ myeloid cells were increased compared to control shRNA expressing cells in BM of Lys05 treated mice, but GFP+ LSK and ST-HSC were not increased (Fig 8C, Fig S7J). These results support a role for p53 in mediating effects of autophagy inhibition in mature leukemic cells but not in LSC. p53 knockdown led to increased GFP+ total cells, myeloid cells, LSK and ST-HSC in BM of AC220 treated mice, indicating that AC220-mediated inhibition of both mature leukemic cells and LSC is p53-dependent. Enhanced p53 activity seen with Lys05 given in combination with AC220 may explain increased inhibition of committed progenitors and mature cells, whereas reduced p53 activity seen with the combination may explain reduced LSC inhibition compared to AC220 alone.

Discussion

Autophagy is a cellular degradation process of adaptation to intracellular and environmental stresses. There is growing evidence that autophagy inhibition can limit growth of established tumors and enhance response to therapy. Our studies show that autophagy inhibition

enhances the sensitivity of human FLT3-ITD AML progenitor cells to TKI and the combination of autophagy inhibition and TKI significantly reduces leukemia burden in FLT3-ITD AML mice. Importantly, autophagy inhibition increases FLT3-ITD AML LSC activation and cycling and depletes their secondary repopulating potential. However, TKI treatment unexpectedly antagonized the ability of autophagy inhibition to deplete repopulating capacity of AML LSC. These results indicate that FLT3-ITD kinase activity drives increased LSC attrition following autophagy inhibition, and autophagy protects FLT3-ITD AML LSC from oncogenic stress. They also indicate that combining TKI treatment with autophagy inhibition differentially affects AML stem cells versus progenitor cells. Finally, they reveal an unexpected, stem cell-specific, antagonistic interaction of autophagy inhibition with FLT3-ITD kinase inhibition.

Quiescent HSC exhibit low oxidative phosphorylation levels and switch to a high oxidative phosphorylation state following activation.^{39, 40} Autophagy-deficient HSC demonstrate increased mitochondrial content accompanied by an activated metabolic state, impaired self-renewal and regenerative potential, and enhanced myeloid differentiation.¹² Here we show that autophagy inhibition leads to mitochondrial accumulation, perturbed mitochondrial function and increased mitochondrial respiratory capacity in AML stem cells. Altered mitochondrial metabolism may explain increased activation and reduced repopulating potential. Attenuation of mitophagy may also contribute to myeloid differentiation, cell cycle arrest, and reduced self-renewal.^{41, 42} Other metabolic changes, including altered lipid metabolism, which has complex interplays with autophagy, may also play a role.⁴³ OXPHOS was markedly downregulated with combined TKI treatment and autophagy inhibition, indicating that increased mitochondrial respiration following autophagy inhibition is FLT3-ITD kinase activity driven, and potentially explaining antagonistic effects of TKI on autophagy inhibition-mediated activation and attrition of AML LSC.

Autophagy inhibition enhanced TKI-mediated targeting of committed progenitors, mature cells and FLT3-ITD cell lines. Autophagy upregulation can be a mechanism for escape from drug treatment. In CML, another tyrosine kinase-dependent leukemia, TKI treatment induces autophagic flux, and combined autophagy inhibition and TKIs treatment enhances eradication of LSC.^{23, 24, 45, 46} FLT3-ITD expression can increase autophagy flux in AML cell lines.³⁴ We observed enhanced sensitivity of FLT3-ITD+ AML progenitors to autophagy inhibition compared to FLT3-ITD negative cells. These results are consistent with a recent study found that identified autophagy as an important mechanism of TKI resistance in FLT3-ITD AML.⁴⁴ However, unlike this and previous studies, we did not observe differences in autophagy flux between FLT3-ITD AML and normal stem and progenitor cells, or increased autophagy flux with TKI treatment, suggesting that FLT3-ITD effects on autophagy may be cell context-dependent.

AML CD34+ cell sensitivity to autophagy inhibition has been associated with intact p53 protein.¹⁸ p53 knockdown prevented TKI-mediated inhibition of both primitive and mature leukemic cells. Our studies suggest that p53 is a substrate for the autophagosome and that autophagy inhibition reduced p53 degradation and increased p53 levels in FLT3-ITD cell lines, and upregulated p53 activity in TKI-treated FLT3-ITD progenitor cells. p53

upregulation following autophagy inhibition may contribute to enhanced TKI-mediated targeting of committed progenitors. On the other hand, autophagy inhibition downregulated p53 activity in TKI-treated AML LSC, potentially contributing to reduced TKI-mediated inhibition of LSC. The mechanisms underlying stage specific differences in p53 regulation are not known and require further investigation.

Efforts for clinical development of autophagy inhibitors include testing of HCQ and derivatives targeting lysosomes, and of inhibitors specifically targeting key autophagy mediators including ULK1⁴⁷ and VPS34.⁴⁸ In clinical trials, HCQ failed to achieve consistent autophagy inhibition at maximum tolerated doses. Deletion or pharmacological inhibition of ULK1 was shown to selectively target CML LSCs when combined with TKI treatment. The current studies demonstrate the potential for autophagy inhibition to activate and impair FLT3-ITD AML LSC function. However, in this setting, oncogenic tyrosine kinase signaling was necessary for LSC activation and depletion, and TKI inhibition antagonized the effects of autophagy inhibition. On the other hand, autophagy inhibition enhanced TKI mediated targeting of AML progenitors. These observations highlighted the complex and differing effects of autophagy inhibition and its ability to sensitize or antagonize effects of specific anti-leukemia treatments, at different stages of leukemia cell maturation and between different leukemias. Importantly, these studies provide a foundation for further investigation of strategies to deplete LSC regenerative capacity in AML and other malignancies.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by NIH grant R01 CA172447 and R01 CA248794 to RB. We thank Drs Victor Darley-Usmar and Balu Chacko at the Comparative Mitochondrial Health Assessment Core for the cellular bioenergetics assays. We thank Vidya Sagar Hanumanthu for providing help with FACS sorting at the UAB Comprehensive Flow Cytometry Core; the UAB Animal resources Center for maintaining mice colonies; Maya Robinson and Amanda Mullens for obtaining and processing human samples; Mason Harris for assistance with animal studies. Immunofluorescence imaging was performed at the High-Resolution Imaging Facility at UAB.

Data Availability Statement:

RNA sequencing data is deposited in NCBI's Gene Expression Omnibus(GEO) and is accessible through GEO Series accession number:GSE169750.

Reference

1. Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. *Blood* 2017; 129(12): 1577–1585. [PubMed: 28159741]
2. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med* 2013 May 30; 368(22): 2059–2074. [PubMed: 23634996]
3. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. *Leukemia* 2014 Aug; 28(8): 1586–1595. [PubMed: 24487413]

4. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. *N Engl J Med* 2019 Oct 31; 381(18): 1728–1740. [PubMed: 31665578]
5. Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. *Blood Adv* 2020 Mar 24; 4(6): 1178–1191. [PubMed: 32208491]
6. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. *Nature* 2012 Apr 15; 485(7397): 260–263. [PubMed: 22504184]
7. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2019 Jul; 20(7): 984–997. [PubMed: 31175001]
8. Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol* 2018 Jun; 19(6): 349–364. [PubMed: 29618831]
9. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. *N Engl J Med* 2013 Feb 14; 368(7): 651–662. [PubMed: 23406030]
10. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. *Cell* 2011 Sep 2; 146(5): 682–695. [PubMed: 21884931]
11. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. *Nature* 2013 Feb 21; 494(7437): 323–327. [PubMed: 23389440]
12. Ho TT, Warr MR, Adelman ER, Lansinger OM, Flach J, Verovskaya EV, et al. Autophagy maintains the metabolism and function of young and old stem cells. *Nature* 2017 Mar 9; 543(7644): 205–210. [PubMed: 28241143]
13. Galluzzi L, Pietrocola F, Levine B, Kroemer G. Metabolic control of autophagy. *Cell* 2014 Dec 4; 159(6): 1263–1276. [PubMed: 25480292]
14. Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. *J Exp Med* 2011 Mar 14; 208(3): 455–467. [PubMed: 21339326]
15. White E. Autophagy and p53. *Cold Spring Harb Perspect Med* 2016 Apr 1; 6(4): a026120. [PubMed: 27037419]
16. Rothe K, Porter V, Jiang X. Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. *Int J Mol Sci* 2019 Jan 22; 20(3): 461.
17. Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Buhler C, et al. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. *Leukemia* 2018 Oct; 32(10): 2189–2202. [PubMed: 29654265]
18. Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffey PJ, et al. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. *Cell Death Dis* 2017 Jul 13; 8(7): e2927. [PubMed: 28703806]
19. Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, et al. Autophagy is dispensable for Kmt2a/Mll-Mllt3/AF9 AML maintenance and anti-leukemic effect of chloroquine. *Autophagy* 2017 May 4; 13(5): 955–966. [PubMed: 28282266]
20. Liu Q, Chen L, Atkinson JM, Claxton DF, Wang HG. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. *Cell Death Dis* 2016 Sep 8; 7(9): e2361. [PubMed: 27607576]
21. Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. *Blood* 2016 Feb 18; 127(7): 882–892. [PubMed: 26286850]
22. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, et al. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. *Leukemia* 2014 Mar; 28(3): 577–588. [PubMed: 24080946]

23. Baquero P, Dawson A, Mukhopadhyay A, Kuntz EM, Mitchell R, Olivares O, et al. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. *Leukemia* 2019 Apr; 33(4): 981–994. [PubMed: 30185934]
24. Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. *Blood* 2011 Aug 25; 118(8): 2035–2043. [PubMed: 21693757]
25. Karvela M, Baquero P, Kuntz EM, Mukhopadhyay A, Mitchell R, Allan EK, et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. *Autophagy* 2016 Jun 2; 12(6): 936–948. [PubMed: 27168493]
26. Sumitomo Y, Koya J, Nakazaki K, Kataoka K, Tsuruta-Kishino T, Morita K, et al. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia. *Blood* 2016 Sep 22; 128(12): 1614–1624. [PubMed: 27480114]
27. Porter AH, Leveque-El Mouttie L, Vu T, Bruedigam C, Sutton J, Jacquelin S, et al. Acute myeloid leukemia stem cell function is preserved in the absence of autophagy. *Haematologica* 2017; 102(9): e344–e347. [PubMed: 28550181]
28. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. *Proc Natl Acad Sci U S A* 2012 May 22; 109(21): 8253–8258. [PubMed: 22566612]
29. Xie M, Kong Y, Tan W, May H, Battiprolu PK, Pedrozo Z, et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. *Circulation* 2014 Mar 11; 129(10): 1139–1151. [PubMed: 24396039]
30. Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, et al. BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. *Nature* 2017 Nov 16; 551(7680): 384–388. [PubMed: 29144447]
31. Abraham A, Qiu S, Chacko BK, Li H, Paterson A, He J, et al. SIRT1 regulates metabolism and leukemogenic potential in CML stem cells. *J Clin Invest* 2019 Jun 10; 129(7): 2685–2701. [PubMed: 31180336]
32. Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, et al. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. *Blood* 2014 May 1; 123(18): 2826–2837. [PubMed: 24668492]
33. Kaizuka T, Morishita H, Hama Y, Tsukamoto S, Matsui T, Toyota Y, et al. An Autophagic Flux Probe that Releases an Internal Control. *Mol Cell* 2016 Nov 17; 64(4): 835–849. [PubMed: 27818143]
34. Heydt Q, Larrue C, Saland E, Bertoli S, Sarry JE, Besson A, et al. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. *Oncogene* 2018 Feb 8; 37(6): 787–797. [PubMed: 29059168]
35. Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. *Cancer Cell* 2015 Apr 13; 27(4): 502–515. [PubMed: 25873173]
36. Li L, Wang ZV, Hill JA, Lin F. New autophagy reporter mice reveal dynamics of proximal tubular autophagy. *J Am Soc Nephrol* 2014 Feb; 25(2): 305–315. [PubMed: 24179166]
37. Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. *Nature* 2016 Dec 15; 540(7633): 433–437. [PubMed: 27926740]
38. van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. *Cell* 2019 Mar 7; 176(6): 1265–1281 e1224. [PubMed: 30827681]
39. Folmes CD, Dzeja PP, Nelson TJ, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. *Cell Stem Cell* 2012 Nov 2; 11(5): 596–606. [PubMed: 23122287]
40. Hsu P, Qu CK. Metabolic plasticity and hematopoietic stem cell biology. *Curr Opin Hematol* 2013 Jul; 20(4): 289–294. [PubMed: 23615055]
41. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. *Cell Stem Cell* 2018 Jul 5; 23(1): 86–100. [PubMed: 29910151]

42. Nguyen TD, Shaid S, Vakhrusheva O, Koschade SE, Klann K, Tholken M, et al. Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. *Blood* 2019 Jan 10; 133(2): 168–179. [PubMed: 30498063]
43. Xie Y, Li J, Kang R, Tang D. Interplay Between Lipid Metabolism and Autophagy. *Front Cell Dev Biol* 2020; 8: 431. [PubMed: 32582708]
44. Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Tholken M, et al. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. *Leukemia* 2022 Aug 23.
45. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. *J Clin Invest* 2009 May; 119(5): 1109–1123. [PubMed: 19363292]
46. Helgason GV, Mukhopadhyay A, Karvela M, Salomoni P, Calabretta B, Holyoake TL. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. *Curr Cancer Drug Targets* 2013 Sep; 13(7): 724–734. [PubMed: 23941517]
47. Martin KR, Celano SL, Solitro AR, Gunaydin H, Scott M, O'Hagan RC, et al. A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress. *iScience* 2018 Oct 26; 8: 74–84. [PubMed: 30292171]
48. Ronan B, Flamand O, Vescovi L, Dureuil C, Durand L, Fassy F, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. *Nat Chem Biol* 2014 Dec; 10(12): 1013–1019. [PubMed: 25326666]




Figure 1. Autophagy inhibition reduces growth of FLT3-ITD cells and enhances sensitivity to TKI treatment in vitro.

A: GFP-LC3-RFP-LC3 Δ G expressing plasmid used to measure autophagy in live cells (left). Flow cytometry sorting strategy and histogram for autophagy flux (AT) high vs AT low cells on Molm13 cell lines (middle). Apoptosis of AT high cells and AT low cells measured by Annexin V and DAPI after exposure to Lys05 (5 μ M) and/or AC220 (2nM) for 48 hours (right). B: Survival of Molm13, MV4-11 and OCI-AML3 cells transduced with ATG5-shRNA expressing lentivirus vectors and cultured for 48 hours with/without AC220 treatment (20nM). C: Survival of Molm13, MV4-11 and OCI-AML3 cells after 48 hours exposure to drugs at indicated concentration. Significance values: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$; ns, not significant. Results represent mean \pm SEM of multiple replicates.




Figure 2. Autophagy inhibition reduces human FLT3-ITD AML CD34+ cell growth and enhances TKI sensitivity in vitro

A: Effect of Lys05 (5μM) and AC220 (20nM) on autophagy flux in FLT3-ITD AML CD34+ cells. LC3B-FITC MFI was measured in by flow cytometry after 24h exposure (n=4-5) (left). LC3B protein expression was measured by Western blotting after 16h treatment from FLT3-ITD AML #178 (middle). LC3B puncta were measured by immunofluorescence microscopy after 4h exposure from FLT3-ITD AML #178 (right). **B:** FLT3-ITD AML CD34+ cells (n=7-8) and non FLT3-ITD AML CD34+ cells(n=4) were treated with Lys05 with/without AC220 for 48 hours, cell survival was measured by AnnexinV and DAPI labeling (left) and cell growth was measured using CellTiter-Glo (right). **C:** FLT3-ITD AML CD34+ cells (n=4) were transfected with ATG5-siRNA and control-siRNA. Western blotting was performed to measure ATG5 protein levels (left). Cell survival (middle) and cell growth (right) and were measured after culture for 48 hours with/without AC220(20nM) treatment. Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Results represent mean ± SEM of multiple replicates.




Figure 3. Autophagy inhibition enhances TKI-mediated targeting of primary human FLT3-ITD cells engrafted in immunodeficient mice

A: Experimental design. Irradiated NSG mice (250cGy) or NRSG mice (400 cGy) were transplanted with peripheral blood mononuclear cells from FLT3-ITD AML patients (5×10^6 cells per mouse, OKT3 antibody incubated). After successful human cell engraftment was confirmed after 8-12 weeks, mice were treated with vehicle, Lys05, AC220 or combination for 3 weeks, and human cells in PB, BM and spleen cells were analyzed (n=3-8). **B:** The percents of human CD45+ cells engrafted in BM of NRSG or NSG mice engrafted with FLT3-ITD AML samples #173, #395 and #591 are shown. **C:** BM cells were labeled with Ki67 and DAPI, and cell cycle of human CD34+CD38- cells from FLT3ITD AML #395 was measured by flow cytometry. Representative cell cycle flow plots and compiled results are shown. Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Results represent mean \pm SEM of multiple replicates.




Figure 4. Autophagy inhibition enhances TKI-mediated inhibition of FLT3 ITD AML progenitors and increases AML stem cell cycling in a genetic mouse model
 A: Experimental plan. BM cells were obtained from FLT3-ITD^{ki} Mx1-cre Tet2^{f/f} CD45.2 mice following leukemia induction and were transplanted into irradiated (400cGy x 2) 8-10 weeks old CD45.1 mice. Blood draws were performed every 2 weeks to check for leukemia development. After 6-8 weeks, mice were treated with vehicle, Lys05 (20mg/kg/day, IP), AC220 (10mg/kg/day, oral gavage), or the combination of AC220 and Lys05 for 2 weeks (n=10-12). B: The flow gating strategy for stem/progenitor subsets is shown (left) and total number of GMP and ST-HSC per 2 femurs and 2 tibiae (4 bones) are shown (right). C: BM cells were labelled with Ki67 and DAPI, and cell cycle analysis was performed (n=6-7). A representative FACS plot and a graph of compiled data for LSK cells are shown. Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Results represent mean ± SEM of multiple replicates.




Figure 5. Autophagy inhibition reduces repopulating capacity of FLT3-ITD AML stem cells in a genetic mouse model

A: Experimental design: FLT3-ITD AML mice were treated for 2 weeks with vehicle, Lys05, AC220 or the combination of Lys05 and AC220, as described for Fig4A, and 2×10^6 BM cells (CD45.2+) obtained from treated mice were injected into irradiated (400cGy \times 2) recipient CD45.1 mice together with 2×10^6 BM cells from wildtype CD45.1 mice (n=6-8). B: Donor myeloid chimerism from peripheral blood were monitored every 4 weeks. The total number of donor GMP and ST-HSC per 2 femurs and 2 tibiae (4 bones) are shown. C: LSK cells isolated from FLT3-ITD^{ki}/Mx1-Cre Tet2^{fl/fl} leukemic BM were transduced with lentivirus vectors expressing ATG5-shRNA and GFP or ctrl-shRNA and GFP. Reduction in ATG5 protein levels in GFP+ cells was confirmed by Western blotting. Engrafted mice were treated with AC220 or vehicle for 2 weeks. Total number of GFP+ GMP and GFP+ ST-HSC in BM of recipient mice (2 femurs and 2 tibias) are shown (n=4-7). Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Results represent mean \pm SEM of multiple replicates.




Figure 6. Enhanced mitochondrial respiration gene signatures in AML LSC following autophagy inhibition

RNASeq analysis was performed on FLT3-ITD AML LSK cells and GMP sorted from Lys05, AC220, combination and vehicle treated mice (4 replicates per group), and Gene-set Enrichment Analysis (GSEA) of differentially expressed genes was performed. A-B: Representative GSEA plot showing downregulation of a quiescence gene set and upregulation of G2M checkpoint gene sets in LSK from Lys05 versus vehicle treated mice (A). Heatmap of expression of quiescence and cell cycling genes in Lys05 treated LSK cells (B). C: Representative plots showing upregulation of oxidative phosphorylation gene sets in LSK from Lys05 versus vehicle treated mice. GSEA plots showing downregulation of OXPHOS gene sets in LSK from mice treated with AC220 versus vehicle, combination of Lys05 and AC220 versus vehicle and combination of Lys05 and AC220 versus Lys05. Significance values: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$; ns, not significant. Results represent mean \pm SEM of multiple replicates.




Figure 7. Reduced mitochondrial respiration in AML stem cells with tyrosine kinase inhibition in combination with autophagy inhibition

A: Mitochondrial DNA (mtDNA) from Lys05 and vehicle treated LSK cells(n=5) was quantified based on ratio of mt-CoxII or mt-CytB to nuclear DNA. B: Mitochondrial membrane potential was measured by TMRE labeling in LSK cells from Lys05 and vehicle treated mice(n=5). C: Extracellular flux analysis for oxygen consumption rate (OCR) was performed on c-Kit enriched cells obtained from FLT3-ITD^{ki} /Mx1-Cre Tet2^{f/f} leukemic mice after 2 weeks of indicated drug treatment (n=4-5). A representative plot and a graph of compiled data are shown. Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Results represent mean ± SEM of multiple replicates.




Figure 8. Autophagy inhibition differentially modulates p53 activity in TKI-treated FLT3-ITD AML progenitor and stem cells

A: Enrichment plot for combination of Lys05 and AC220 compared with AC220 treatment for GMP cells (left). The expression of p53 target genes, p21, Bax, Noxa and Puma, measured by Q-RT-PCR in GMP cells treated with the Lys05 or/and AC220 for 2 weeks in vivo (n=3-5) (middle). Expression of p53 target genes, p21, BAX, NOXA and PUMA, in FLT3-ITD AML CD34+ cells after treatment with Lys05 or/and AC220 for 48 hours (n=4) (right). B: Enrichment plot for combination of Lys05 and AC220 compared with AC220 treatment for LSK cells (left). The expression of p53 target genes, p21, Bax, Noxa and Puma, measured by Q-RT-PCR in LSK cells treated with the Lys05 or/and AC220 for 2 weeks in vivo (n=3-5) (right). C: LSK cells isolated from FLT3-ITD^{ki}/Mx1-Cre Tet2^{f/f} leukemic BM were transduced with lentivirus vectors expressing P53-shRNA and GFP or ctrl-shRNA and GFP. Engrafted mice were treated with Lys05, AC220 or vehicle for 2 weeks. Reduction in P53 protein levels in GFP+ cells was confirmed by Western blotting. Total number of GFP+ myeloid cells and GFP+ ST-HSC in BM of recipient mice (2 femurs and 2 tibias) are shown (n=3-5). Significance values: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001; ns, not significant. Results represent mean \pm SEM of multiple replicates.